Savitz Ryan

CFO Ryan Savitz sells 8.2K shares of DNTH at $89.84, exiting full position as stock near 52-week high

Ryan Savitz, EVP, CFO & CBO, sold 8,224 shares at $89.84 on 2026-04-09, completely liquidating his holdings and raising $738.8K. The sale occurred near the 52-week high—the stock is currently -2.1% from its $91.66 peak and up 135.1% over 90 days. Notably, Savitz executed five separate sell transactions at DNTH on 2026-03-31 just days prior, and his cross-ticker track record shows 10 prior sells with a 90-day well-timed rate of 0.00%, indicating a pattern of selling into strength rather than before declines. The underlying company is unprofitable (full-year net income was $-36.8M) with severely declining revenues (-67.4% year-over-year) and minimal quarterly revenue of $396.0K, creating a material disconnect between the stock's valuation and operational performance.

CFO Ryan Savitz sells entire 114.4K share stake in DNTH for $9.5M across 8 transactions on 2026-03-31

Ryan Savitz, EVP, CFO & CBO, executed 8 separate sales totaling 114,367 shares for $9,492,595.50, liquidating his entire position at prices ranging from $78.33 to $85.54 (blended average $83.00). The complete exit occurs in a company context marked by severe financial stress: latest-quarter revenue was $396,000.00, net income was $-36,765,000.00, and annual revenue has contracted -67.4% year-over-year, while market cap remains $3.8B. Notably, Savitz's prior two sales at DNTH (on 2025-12-04 and 2025-09-09) saw the stock rise 37.3% and 24.6% respectively in the 90-day periods following those sales—a 0 of 2 well-timed rate—meaning he has historically sold before material rallies at this ticker. Current price is $84.56, only -2.7% below the 52-week high of $86.92, and the stock has surged +53.0% over 30 days and +105.2% over 90 days, placing this sale near peak recent valuations after an extended rally.

CFO Ryan Savitz sold entire 20,000-share stake in DNTH for $903.6K on Dec 4 as stock near 52-week high

Ryan Savitz, CFO & CBO of Dianthus Therapeutics, liquidated his complete position of 20,000 shares at $45.18, reducing holdings to zero and raising $903,600.00. The sale occurred when DNTH was trading -1.0% from its 52-week high of $44.71, and the stock has risen 31.2% over the prior 30 days and 67.0% over 90 days. Dianthus is an unprofitable biotech company (net income of $-36.8M in its most recent full fiscal year) with minimal quarterly revenue of $396.0K, though it has demonstrated strong annual revenue growth of 120.6% year-over-year. The complete exit of the CFO's stake, combined with the stock's recent sharp appreciation from depressed levels, represents a material reduction in insider commitment to the company at an inflection point in valuation.

CFO Ryan Savitz exits entire DNTH position (20,000 shares at $35.00 for $700,000); stock up 90.2% in 30 days.

Ryan Savitz, serving as CFO and CBO, sold his complete 20,000-share holding at $35.00 for $700,000.00, leaving zero shares post-transaction. The sale occurs amid exceptional recent price momentum: the stock has risen 90.2% over the preceding 30 days and 106.8% over 90 days, reaching $37.86 just days after the transaction. This represents the complete liquidation of his holdings during a period of strong upward trajectory. The company remains unprofitable with net income of $-31.6M in its most recent fiscal year, though annual revenue grew 120.6% year-over-year, suggesting the stock appreciation reflects growth expectations rather than current profitability. A CFO exiting their entire position at elevated valuations—shortly before further gains—warrants investor attention to whether the insider views fundamentals as failing to justify current prices.